Barbara Duncan has served on the Halozyme Board of Directors since 2023, where she chairs the Audit Committee and serves on the Compensation Committee. She brings over 16 years of pharmaceutical and biotechnology industry experience and is an audit committee financial expert.
Ms. Duncan retired from Intercept Pharmaceuticals, Inc., where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016. From 2001 to 2009 she held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., including Chief Financial Officer and ultimately Chief Executive Officer prior to DOV's sale in 2010 to Euthymics Bioscience, Inc. Prior to DOV, she served as Vice President of Corporate Finance, Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989.
Ms. Duncan received her BBA from Louisiana State University and her MBA from The Wharton School of the University of Pennsylvania.